Oct 15, 2019
The Equine Medical Research Fund was created in 2014 to provide consistent funding for equine medical research, which has historically been underfunded. A $1.00 starter fee was added to each USEA recognized event entry beginning in 2014, and at years end a majority of those dollars were distributed through the Morris Animal Foundation, which assists the USEA with selecting studies to fund, monitoring the funds, and reporting on progress. Morris has decades of experience in reviewing grant applications from universities and research institutions and has a team of veterinarians who spend thousands of volunteer hours assessing which studies are most likely to impact horse welfare. Ultimately, a committee from the USEA comprised of riders and veterinarians will determine which studies the USEA dollars will target.
This years committee recommendation is a bit different as the committee is recommending spreading funds among three entities - the Stephen Teichman Farrier study, a Grayson Jockey Club Research Foundation study, and two Morris Animal Foundation Studies.
Through these partnerships, the USEA is helping to address the major problem of equine research underfunding while maintaining control over how member dollars are distributed. Although the committee is always interested in recommending studies that concern general horse welfare, this year we took a closer look at recommending studies that were geared to solving issues that concern performance horses. The goal of our selection philosophy is to provide USEA positive PR through funding a variety of institutions and studies that show our support for horse care, welfare, and rehabilitation.
In 2017, $46,900 dollars were distributed between five different studies on different topics pertaining to equine health, from improving regenerative therapies to studying gaps in the equine genome related to tendon health.
In 2018, $44,858 dollars were distributed between four different studies on a variety of topics including insulin's relation to laminitis, stem cell therapies, equine asthma, and joint infections.
At the USEA Board of Governors meeting in August, the Equine Medical Research Committee recommended the funding of four studies using the $39,581 collected in 2018 and the Board approved their recommendation. Below are additional details about the four selected studies.
Non-Invasive Evaluation of Host-Microbiota Interactions Canaan Whitfield-Cargile, Texas A&M
Summary: This study aims to develop a non-invasive platform to serve as a diagnostic test for gastrointestinal inflammation prior to severe disease and to reveal how bacteria in the gut influence horse health.
Description: One of the most important and common classes of diseases affecting horses are gastrointestinal (GI) diseases including colic and colitis. Despite tremendous research efforts to both diagnose and prevent these diseases, they remain very common and frequently are not diagnosed until severe disease is present. One area that is gaining recognition as an important player in equine GI health and disease is GI bacteria or the microbiota. The microbiota consists of all of the bacteria and other microorganisms in the GI tract. Alterations in the amounts and types organisms that make up the microbiota have been linked to both GI and non-GI diseases of horses including colic, colitis, laminitis, and obesity. These findings are part of the reason why there are a vast array of prebiotics, probiotics, and other products on the market that claim to influence the GI microbiota. Unfortunately, there is minimal evidence to support the efficacy of these products and a lack of understanding of how these products work. A major contributor to the lack of evidence and understanding of these products is related to an inability to monitor the health and function of the equine GI tract. It is clear when severe disease is present but currently impossible to monitor subtle changes. Similarly, while we can easily diagnose severe inflammation and microbiota changes during disease, we cannot capture the changes that occurred prior to clinical disease. These limitations result in capturing results of GI injury and disease but not causes. Consequently, there is great need for improved understanding of the causes of disease and early identification of horses at-risk of developing GI disease. In the absence of such knowledge, effective intervention strategies to reduce GI and GI-related health risks will remain elusive.
Horses and other animals naturally shed cells lining the GI tract on a daily basis. People, in fact, shed up to 1/3 of the cells lining their GI tract daily. We have developed a technique for examining the gene expression profile of these cells to monitor the health and function of the GI tract from fecal samples. We have shown that this approach offers a promising means to non-invasively examine the response of the GI intestinal tract to injury. Further, we have convincing preliminary data demonstrating that the gene expression profile arising from these cells mirrors the gene expression profile of the tissues within the GI tract of the horse and provides a global view of the health and function of the GI tract. This approach offers a highly attractive, non-invasive means of monitoring GI responsiveness to disease and interventions. Thus, our long-term goals are to 1) develop inexpensive, non-invasive diagnostic tests in order to document GI inflammation prior to the onset of severe disease in horses; and, 2) by examining host and microbiota data simultaneously we aim to elucidate the mechanisms of host-microbiota interactions in the context of health and disease. Ultimately, we aim to use this approach to identify specific pathway by which the host and microbiota interact so that this critically important interaction can be targeted therapeutically.
In order to achieve our goals, we will utilize a reversible model of GI inflammation with which we have extensive experience. We will induce GI inflammation with the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone and noninvasively interrogate the response and response of the microbiota. Importantly, we will collect samples sequentially both before and after induction of inflammation in order to gain predictive and diagnostic information about GI inflammation in horses. This approach will have broad application to many equine intestinal disorders and will provide the much needed mechanistic insight into disease development and progression, thereby enabling us to develop effective prevention and treatment strategies for equine GI disease.
The total cost of this study is $46,756 in 2019 and $45,814 in 2020. The EMRC recommends $12,000 for funding this study.
Paraoxonase-1 Activity as a Marker for Diagnosis of Equine Metabolic Syndrome Gabriele Rossi, DVM, Ph.D., DECVCP Murdoch University
Summary: Researchers will investigate a new laboratory test to improve diagnosis of equine metabolic syndrome, a metabolic and hormonal disorder in horses.
Description: Equine metabolic syndrome (EMS) is characterized by abnormal insulin regulation, obesity, and susceptibility to laminitis. EMS is challenging to diagnose since laboratory tests fail to distinguish EMS from other common equine diseases. Human metabolic syndrome (HMS) shares similar laboratory features to EMS and a new serum biomarker has been proposed in human medicine to improve the diagnosis of HMS. Researchers will investigate if this new HMS test also can provide an accurate diagnosis for horses with EMS. A new efficient and cost-effective EMS test will help veterinarians better diagnose and manage this complex disease in horses.
The total cost of this study is $9,355. The EMRC recommends $9,355 to fund this study.
Cell-mediated immunogenicity and MHC expression regulation of TGF-beta2-treated mesenchymal stem cells for improved clinical use in the horse. Lauren V Schnabel, DVM, Ph.D., DACVS, DACVSMR North Carolina State University
Summary: Researchers will manipulate the expression of immune markers on stem cells to develop safer and more effective therapies for horses with musculoskeletal injuries.
Description: Stem cell therapies have the potential to improve the outcome of potentially severe and life-ending musculoskeletal injuries in horses. However, sometimes the recipients immune system will destroy transplanted stem cells if the immune system perceives the introduced cells as foreign. To improve stem cell treatment success, researchers will examine if a novel cell culture treatment can be used to prevent the immune system from destroying donor stem cells. This study will help researchers better understand the cellular regulation of the molecules that initiate immune responses and advance the development of convenient and effective off-the-shelf stem cell therapy.
The total cost of this study is $131,479. The EMRC recommends $12,000 to fund this study. This is the second year that we are recommending funding this 3 year study.
Stephen Teichman Study
The goal is to determine the effects of front shoe surface modifications in the sport horse on the duration of breakover. We discussed and agreed to support this study during the May BOG conference call providing the publishing and professional fees were researched and found to be reasonable, which they were.
The total cost of this study is $9,640. The EMRC recommends USEA to provide $4,820 and an additional $4,820 is to be contributed by other donors.
This brings the total recommended research total to $38,175, leaving $1,406 of use at another time.
For an update on studies previously selected for funding by the USEA Equine Medical Research Committee, click here. To learn more about how the Equine Medical Research Fund got started, click here. For additional information about the Fund, click here.
- Allogene Moves Forward With CAR-T Therapy Pipeline - Seeking Alpha - November 12th, 2019
- Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset - CBS Dallas / Fort Worth - November 12th, 2019
- Heart-warming moment OAP meets mum who saved his life with anonymous stem cell donation after three years of - The Sun - November 12th, 2019
- CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer - GlobeNewswire - November 12th, 2019
- Editas and Celgene sub Juno are tackling hottest immunotherapy cells - Endpoints News - November 12th, 2019
- Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic... - November 11th, 2019
- Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma - Hematology Advisor - November 11th, 2019
- Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - Yahoo Finance - November 11th, 2019
- Gary Pesselt: Vitality Healthcare is it worth the cost? - The Union of Grass Valley - November 11th, 2019
- Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research - GuruFocus.com - November 11th, 2019
- Cancer Stem Cells (CSCs) Market 2019 | Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2025 - Business Daily Mirror - November 11th, 2019
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Weekly Spy - November 11th, 2019
- Ixazomib Extends Survival in Multiple Myeloma for Patients Not Treated With Stem Cell Transplantation - Pharmacy Times - November 10th, 2019
- Phase III trial of Ninlaro as first-line maintenance therapy meets PFS in multiple myeloma - The Cancer Letter - November 10th, 2019
- Roll Over Yamanaka: Meet The Cell Therapy Company Bypassing iPSCs - Scrip - November 10th, 2019
- Tears And Joy This Toddler with Down Syndrome Who Was Battling Leukemia Is Finally Cancer Free - SurvivorNet - November 10th, 2019
- Tales of medical misinformation and misadventures - Stuff.co.nz - November 10th, 2019
- AgeX Therapeutics to Present at Investing in the Age of Longevity Conference - Business Wire - November 10th, 2019
- 'My shock cancer scare and the anonymous German who saved me' - Birmingham Live - November 10th, 2019
- Laura Beil's New Podcast Bad Batch Sheds Light on the World of Unregulated Stem Cell Treatment - D Magazine - November 6th, 2019
- Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting - Business... - November 6th, 2019
- bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition - Financial... - November 6th, 2019
- Three Podcasts to Listen to in November - The New Yorker - November 6th, 2019
- Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs -... - November 6th, 2019
- 19-28z CAR-T Therapy in Children and Young Adults With Relapsed/Refractory ALL: Promising Early Results - Cancer Therapy Advisor - November 6th, 2019
- Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -... - November 6th, 2019
- MD Anderson on a Roll with Another Pharma Deal, This Time with Artios and ShangPharma - BioSpace - November 6th, 2019
- Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual... - November 6th, 2019
- Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's... - November 6th, 2019
- Transient Wave of Hematopoietic Stem Cell Production in Late Fetuses and Young Adults - Technology Networks - November 6th, 2019
- Three UCLA scientists receive grants totaling more than $18 million - UCLA Newsroom - November 4th, 2019
- Can This Cell Therapy Help Fight the NASH... - Labiotech.eu - November 4th, 2019
- Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics - Seeking Alpha - November 4th, 2019
- Galera Therapeutics And Amgen In Severe Oral Mucositis - Seeking Alpha - November 4th, 2019
- The Curious Case Of Enochian Biosciences: Value Out Of Thin Air - Price Target $1 - Seeking Alpha - November 4th, 2019
- Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress - BioSpace - November 4th, 2019
- Stem Cell Banking Market Anticipated to Grow at a Significant Pace by 2028 - Weekly Spy - November 4th, 2019
- Stempeutics to receive US patent for Stempeucel - BSI bureau - November 4th, 2019
- How Stem Cells Can Heal The Body - Version Weekly - November 4th, 2019
- Light-activated pancreatic cells produce insulin on demand - New Atlas - November 4th, 2019
- Future Outlook: Animal Stem Cell Therapy Market 2019- 2025| Research Methodologies Offers High Business Outlook growth - Pledge Times - November 4th, 2019
- Surgeon banned over 'quack' procedures and 'reckless disregard' for safety - Sydney Morning Herald - November 3rd, 2019
- Five-year-old leukaemia patient Zachary White spots Nessie on dream-come-true Scotland trip - Extra.ie - November 3rd, 2019
- An Expert Discusses PARP Inhibition, Vaccines and Emerging Therapies in Kidney Cancer - Curetoday.com - November 3rd, 2019
- Leukaemia: what is it, how to spot the warning signs and who is at risk? - The Telegraph - November 3rd, 2019
- Restore your crowning glory with recombinant DNA tech - The New Paper - November 3rd, 2019
- Is blood cancer curable at an early stage? - The Indian Awaaz - November 3rd, 2019
- Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services - November 2nd, 2019
- The Science Of Stem Cell Research Hits A Snag With Bad Batch - Forbes - November 2nd, 2019
- Mallinckrodt Announces UVADEX (Methoxsalen) Approved in Australia for use with the THERAKOS CELLEX Photopheresis System for Treatment of Chronic Graft... - November 2nd, 2019
- AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - P&T Community - November 2nd, 2019
- Q&A: Draper's Jenna Balestrini on the future of CAR-T - - pharmaphorum - November 2nd, 2019
- Organ donations: What you can do to help save a life - Calgary Herald - November 2nd, 2019
- Six ways cancer is treated - The Standard - November 2nd, 2019
- Stem cell therapy approved for MS patients in Scotland - HeraldScotland - October 29th, 2019
- Battle brews over how tightly to regulate new cancer treatment - Crain's Detroit Business - October 29th, 2019
- Quadruple Therapy for Newly Diagnosed Patients With MM Shows PFS Benefit Over Triple Therapy - AJMC.com Managed Markets Network - October 29th, 2019
- Some animals pause their own pregnancies, but how they do it is still a mystery - The Conversation AU - October 29th, 2019
- Tiger Woods wins, Gary McCord and Peter Kostis out at CBS, and Brooks Koepka (knee) to miss more time: What you missed - Golf Digest - October 29th, 2019
- Hormones Control your Health, Mood and Behavior A balanced hormone means happier, healthier life and success in career and relationship. - Magazine of... - October 29th, 2019
- Stem cell registry gets good response - The New Indian Express - October 29th, 2019
- The Stars in Our Brains - Duke Department of Neurology - October 29th, 2019
- Brooks Koepka not in the field at the WGC-HSBC Champions, status of his knee injury remains unclear - Yahoo Sports - October 29th, 2019
- Cynata Therapeutics awarded grant to progress stem cell therapies for coronary artery disease - Proactive Investors Australia - October 29th, 2019
- How Ruthin mum's family tragedy became her driving force to save lives - Daily Post - October 29th, 2019
- Cork father of boy with bone disease hopes his book will inspire others to celebrate difference - Irish Examiner - October 29th, 2019
- What is aplastic anemia? Symptoms, causes, and treatment - Medical News Today - October 25th, 2019
- American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public - P&T Community - October 25th, 2019
- Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 Process A... - October 25th, 2019
- Anthony Harries: In the absence of a true test for latent TB we need shorter, safer preventive treatments - The BMJ - The BMJ - October 25th, 2019
- Quality of Life Is Similar in Older Patients Receiving Intensive vs Nonintensive Chemotherapy - Hematology Advisor - October 25th, 2019
- Speaking Multiple Sclerosis: A Glossary of Common Terms - Everyday Health - October 25th, 2019
- Veterans Day: Flotation Therapy Helping Special Operations Officer - Yahoo Finance - October 25th, 2019
- Dad who called on the public for stem cells for his son is up for an award - Chronicle Live - October 25th, 2019
- In a first, 26-year-old DMD patient in UP survives with stem cell therapy - India TV News - October 25th, 2019
- Progress toward improving detection, monitoring and treatment of metastatic cancers - Brain Tumour Research - October 25th, 2019
- BrainStorm Cell Therapeutics' President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019 - GlobeNewswire - October 25th, 2019
- Bloomington Vet Joins Study For Stem Cell Therapy To Treat Dogs With Arthritis - WGLT News - October 24th, 2019
- NIH and Gates Foundation lay out ambitious plan to bring gene-based treatments for HIV and sickle cell disease to Africa - Science Magazine - October 24th, 2019
- Stem Cell Therapy Market Will Achieve 10.2% CAGR to Cross $15bn by 2025: Global Market Insights, Inc. - Herald-Mail Media - October 24th, 2019